Skip to main content
. Author manuscript; available in PMC: 2014 Feb 25.
Published in final edited form as: Gene Ther. 2009 Dec 17;17(2):158–170. doi: 10.1038/gt.2009.161

Figure 6. Immune responses after intratumoral injection of live and inactivated forms of VSV and therapeutic efficacy of intratumoral TLR agonist in B16ova tumors.

Figure 6

Figure 6

A. Subcutaneous B16ova tumors were infected with 3 daily injections of either live or inactivated VSV (5×107 pfu/injection). Eight days after the last virus, spleens were harvested, dissociated and incubated with one of the four antigens indicated. Total IFN-γ spots (1×105 splenocytes/48h) were measured using ELISPOT (n=3 mice/group). B. At the time of sacrifice (day 17 after tumor challenge), blood was also extracted and serum neutralizing antibody titer was determined. *p<0.05, **p<0.01, ***p<0.001. C. RT-PCR for type I interferon-responsive genes was performed on total RNA from subcutaneous B16ova tumors—harvested 8 hours postinfection—given a single injection of 5×108 pfu either live or inactivated VSV. D. Kaplan-Meier survival plot of B16ova tumor-bearing C57Bl/6 mice (n=8 per group) treated with three (3) intratumoral injections of either VSV-GFP (5×108 pfu/dose) or 200 μg of lipopolysaccharide (LPS). *p<0.05, **p<0.01, ***p<0.001.